Changes in Hospital Quality Associated with Hospital Value-Based Purchasing

Abstract

BACKGROUND Starting in fiscal year 2013, the Hospital Value-Based Purchasing (HVBP) program introduced quality performance–based adjustments of up to 1% to Medicare reimbursements for acute care hospitals. METHODS We evaluated whether quality improved more in acute care hospitals that were exposed to HVBP than in control hospitals (Critical Access Hospitals, which were not exposed to HVBP). The measures of quality were composite measures of clinical process and patient experience (measured in units of standard deviations, with a value of 1 indicating performance that was 1 standard deviation [SD] above the hospital mean) and 30-day risk-standardized mortality among patients who were admitted to the hospital for acute myocardial infarction, heart failure, or pneumonia. The changes in quality measures after the introduction of HVBP were assessed for matched samples of acute care hospitals (the number of hospitals included in the analyses ranged from 1364 for mortality among patients admitted for acute myocardial infarction to 2615 for mortality among patients admitted for pneumonia) and control hospitals (number of hospitals ranged from 31 to 617). Matching was based on preintervention performance with regard to the quality measures. We evaluated performance over the first 4 years of HVBP. RESULTS Improvements in clinical-process and patient-experience measures were not significantly greater among hospitals exposed to HVBP than among control hospitals, with difference-in-differences estimates of 0.079 SD (95% confidence interval [CI], −0.140 to 0.299) for clinical process and −0.092 SD (95% CI, −0.307 to 0.122) for patient experience. HVBP was not associated with significant reductions in mortality among patients who were admitted for acute myocardial infarction (difference-in-differences estimate, −0.282 percentage points [95% CI, −1.715 to 1.152]) or heart failure (−0.212 percentage points [95% CI, −0.532 to 0.108]), but it was associated with a significant reduction in mortality among patients who were admitted for pneumonia (−0.431 percentage points [95% CI, −0.714 to −0.148]). CONCLUSIONS In our study, HVBP was not associated with improvements in measures of clinical process or patient experience and was not associated with significant reductions in two of three mortality measures. (Funded by the National Institute on Aging.)

Impact of oral anticoagulants on 30-day readmission: a study from a single academic centre

“…Agency for Healthcare Research and Quality finds that nearly one in five of all hospital patients covered by Medicare are readmitted within 30 days, costing $15 billion a year 20. The Hospital Value-based Purchasing Program started in 2013 making value-based incentive payments to acute care hospitals 21. Short-term acute-care hospitals are reimbursed under the inpatient prospective payment system (IPPS) 19.…”

The effects of a schizophrenia pay‐for‐performance program on patient outcomes in Taiwan

“…6 We matched patients in the P4P group to patients in the control group based on preintervention levels of adverse outcomes and covariates (confounders). 7 However, to avoid a risk of regression to the mean (RTM) and the consideration of a covariate as an instrumental variable, we followed Daw and Hatfield's suggestions on selecting matching variables for DID analysis to test the preintervention differences between the P4P intervention and control group at the adverse outcome and covariate levels. 8 We further employed the DID analysis for each adverse outcome after PSM.…”

Toward Value in Health Care

“…Theoretically, these programs incentivize providers to select higher value services by incentivizing low-cost care while penalizing or rewarding based on care quality. However, preliminary evidence suggests little effect, with both quality measures and costs stagnating [14,15].…”